Insulin-like growth factor-1 gene therapy - Valentis

Drug Profile

Insulin-like growth factor-1 gene therapy - Valentis

Alternative Names: IGF-1 gene therapy - Valentis; Somatomedin-1 gene therapy - Valentis

Latest Information Update: 31 Aug 2007

Price : $50

At a glance

  • Originator Valentis
  • Class Antihyperglycaemics; Gene therapies; Growth factors
  • Mechanism of Action Gene transference; Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetic neuropathies; Genitourinary disorders; Postmenopausal osteoporosis

Most Recent Events

  • 03 Feb 2003 A preclinical study has been added to the Genitourinary disorders pharmacodynamics section
  • 22 Jun 1999 The merged company of GeneMedicine and Megabios is now called Valentis
  • 29 Mar 1999 GeneMedicine has merged with Megabios
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top